Valproate for Mood Swings and Alcohol Use Following Head Injury

This study is ongoing, but not recruiting participants.
Department of Defense
Information provided by (Responsible Party):
University of Colorado, Denver Identifier:
First received: November 8, 2012
Last updated: December 11, 2014
Last verified: December 2014

Despite the body's natural healing during the first year after a head injury, many veterans who have suffered even mild brain injuries find themselves easily upset or fearful as they go about their daily lives. While these reactions to the world around them were easily managed before the head injury, they now occur with little or no interruption and are exceedingly difficult to manage. Such reactions include a sense of always being upset or fearful that often makes it difficult to get along with family members, friends, coworkers, and employers. This may lead to broken marriages, unemployment, and even homelessness.

Some people with head injuries try to manage their unmanageable moods by drinking alcohol because it can create a sense of calm. However, alcohol's actions are short in duration. Most find that they have to drink more and more for a similar calming effect, and they soon become dependent on alcohol. This makes working and being part of their families even more difficult.

To treat the unmanageable mood, we tried a medicine called valproate, one that eases mood problems in people without head injury. We gave valproate to head injured persons with mood problems in a "non-blinded" study where both the doctor and the patient knew that the medicine was valproate and both were optimistic that it would work. In a small sample of eighteen people, 85% found mood relief and most of those either stopped drinking alcohol or drank much less than before. However, this might have been because both the doctor and patient were hopeful that the medication would make the patient feel better or because the medicine actually worked.

The only way to know for sure if the medicine works is to perform a study in which people receive either valproate or a sugar pill while neither they nor their doctor know which one they are taking. This is called a double blind study, as proposed here, and will involve nearly three times as many head injured persons as the first study.

If it is successful, the new study will show that valproate treatment helps head injured people manage their moods and allows them to return to families, friends, and work. It will also show that they drink alcohol less or not at all, improving their health even further. Then doctors will know that they can use this medicine for large numbers of people who suffer from head injury and help them to lead normal lives. If the outcome of the study shows that the medicine works well, doctors can then use this medicine to treat people with head injury immediately after the study results are published.

Condition Intervention
Traumatic Brain Injury (TBI)
Drug: divalproex sodium
Drug: Placebo

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Double Blind Trial of Divalproex Sodium for Affective Lability and Alcohol Use Following Traumatic Brain Injury

Resource links provided by NLM:

Further study details as provided by University of Colorado, Denver:

Primary Outcome Measures:
  • Affective Lability [ Time Frame: Weeks 1-10 ] [ Designated as safety issue: No ]
    Symptom frequencies of affective lability will be measured weekly using the Agitated Behavior Scale and Neurobehavioral Rating Scale (Revised).

Secondary Outcome Measures:
  • Alcohol Use [ Time Frame: Weeks 1-10 ] [ Designated as safety issue: No ]
    Frequencies of alcohol use/misuse will be measured weekly utilizing the Timeline Followback assessment. Participants will also be given an alcohol breath test at every clinic visit.

Estimated Enrollment: 50
Study Start Date: September 2008
Estimated Study Completion Date: August 2015
Primary Completion Date: August 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: divalproex sodium Drug: divalproex sodium
Doses will be given in 250mg increments and titrated over the first four days of study until a starting dose of 750 mg is reached. The Study Oversight Team, who is not involved in any clinical visits, will be un-blinded to study drug assignment and will have plasma concentration results and adverse event reports available to them. If a subject has no adverse events and is not at therapeutic level as indicated by the blood levels, the Study Oversight Team may inform the research pharmacy to increase the dose by 1 tablet of 250 mg to 1000 mg per day. The Study Oversight Team may also inform the research pharmacy to reduce the daily dosage back down to 750 mg per day if plasma concentrations or adverse events become intolerable. The maximum dose for the purpose of this study will be 1250 mg daily and the minimum dose will be 750 mg daily. Subjects who cannot tolerate the minimum dose will be excluded from any further study participation.
Placebo Comparator: sugar pill Drug: Placebo
Doses will be titrated over the first four days of study in the same manner as the active study drug. After titration, the research pharmacy may increase the dose by 1 tablet per day, in the same fashion that the active drug may be adjusted, so that the participant and clinical team remain blinded to the drug assignment. The research pharmacy may also reduce the daily dosage back down by one tablet per day for the same reason.
Other Name: sugar pill


Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Veteran
  • history of closed-head traumatic brain injury (TBI) at least one year prior to enrollment
  • symptoms of affective lability such as mood swings, irritability, frustration and anxiety
  • currently using alcohol

Exclusion Criteria:

  • history of Axis I bipolar disorder or anxiety disorder prior to the TBI
  • skull opened either surgically or traumatically
  • history of stroke
  • current diagnosis or past history of major psychosis as defined by Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)
  • active liver disease
  • evidence of the alcohol amnesic syndrome
  • history of seizure disorder other than those caused by ethanol withdrawal
  • any type of dementia
  • current suicidal/homicidal ideations
  • symptomatic thiamine, folate or Vitamin B-12 deficiency
  • HIV positive
  • any medical conditions that would constitute contraindications to treatment with divalproex sodium
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01760785

United States, Colorado
Denver Veteran's Affairs Medical Center
Denver, Colorado, United States, 80220
Sponsors and Collaborators
University of Colorado, Denver
Department of Defense
Principal Investigator: Thomas P Beresford, MD Denver Veteran's Affairs Medical Center
  More Information

No publications provided

Responsible Party: University of Colorado, Denver Identifier: NCT01760785     History of Changes
Other Study ID Numbers: 08-0582, PT075168
Study First Received: November 8, 2012
Last Updated: December 11, 2014
Health Authority: United States: Institutional Review Board
United States: Food and Drug Administration

Keywords provided by University of Colorado, Denver:
Traumatic Brain Injury(TBI)

Additional relevant MeSH terms:
Brain Injuries
Alcohol-Related Disorders
Brain Diseases
Central Nervous System Diseases
Chemically-Induced Disorders
Craniocerebral Trauma
Mental Disorders
Nervous System Diseases
Substance-Related Disorders
Trauma, Nervous System
Wounds and Injuries
Valproic Acid
Antimanic Agents
Central Nervous System Agents
Central Nervous System Depressants
Enzyme Inhibitors
GABA Agents
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Pharmacologic Actions
Physiological Effects of Drugs
Psychotropic Drugs
Therapeutic Uses
Tranquilizing Agents processed this record on October 09, 2015